drugset

drugset / Trial / NCT05045248

Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis

NCT05045248 ↗

Phase 2 Completed 10 enrolled American University of Beirut Medical Center

NaSingle-groupOpen-labelTreatment

Summary

This study is aimed at assessing the efficacy of Apraclonidine eye drops in the treatment of ptosis secondary to myasthenia gravis.

Timeline

Start: 2020-06-01
Primary completion: 2021-04-15
Completion: 2021-04-15

Publications

Agha M, Ismail H, Sawaya R, Salameh J. Efficacy of apraclonidine eye drops in treating ptosis secondary to myasthenia gravis: A pilot clinical trial. Muscle Nerve. 2023 Aug;68(2):206-210. doi: 10.1002/mus.27851. Epub 2023 May 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Apraclonidine	Small molecule	0.5 %	Other

Indications